Education

• 2001-2005   B.S. College of Pharmacy, Chungbuk National University, Republic of Korea
• 2005-2007   M.S. Department of Pharmaceutics, College of Pharmacy, Chungbuk National University, Republic of Korea
• 2007-2012   Ph.D. Department of Pharmaceutics, College of Pharmacy, Chungbuk National University, Republic of Korea

Career

• 2012-2015   Research Fellow, Research Center for Cell Fate Control (RCCFC) & College of Pharmacy, Sookmyung Women’s University, Seoul, Republic of Korea
• 2015-2017   Research Associate, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, WI, USA
• 2017-2018   Assistant Professor, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan, Republic of Korea
• 2019-2020   Visiting Professor, Institut de Bioenginyeria de Catalunya (IBEC), Barcelona, Spain
• 2024-2025   Visiting Professor, Universitat Politècnica de València (UPV), Valencia, Spain
• 2018-present   Associate Professor, College of Pharmacy, Chungbuk National University, Cheongju, Republic of Korea
• 2021-present   CEO, Korea Animal Replacement Experiment (KARE), Cheongju, Republic of Korea. www.kare.re.kr
• 2024-present   Adjunct Associate Professor, Biomedical Research Institute, Chungbuk National University Hospital, Cheongju, Republic of Korea

Research Areas

1. Nanotechnology-based drug delivery systems (micelles, liposomes)

2. Local drug delivery systems (hydrogel, gel-forming powder)

3. Targeting of cancer stem cells

4. Pharmacokinetics and pharmacodynamics (PK/PD)

5. Interspecies scaling and human pharmacokinetic parameter prediction

6. Animal replacement technologies and alternative experimental models

Selected Publications

1. Recapitulating In Vivo Pharmacokinetics and Size-Dependent Nanomedicine Delivery in a Microfluidic Platform, Su Jeong Kang, Moon Sup Yoon, Jae Min Lee, Min Jeong Jo, Chae Eun Jin, and Dae Hwan Shin*, Advanced Science, Accepted (2026)
2. Sequential gemcitabine and panobinostat-loaded albumin nanoparticle delivery via thermosensitive hydrogel in pancreatic peritoneal metastasis, Jae Min Lee, Moon Sup Yoon, Min Jeong Jo, Su Jeong Kang, Sunghyun Bong, Chae Eun Jin, Ji-hyun Park, Hwan Ma, Kyu Ha Lee, Yoon Seok Roh, Chan-Su Park, Chun-Woong Park, and Dae Hwan Shin*, Journal of Controlled Release, 395 (2026)
3. Recent Advances in Nanoscale Sprayable Hydrogels for Cancer Management: Nanoparticle-Loaded Formulations for Therapy and Prevention, Jae Min Lee*, Su Jeong Kang*, Moon Sup Yoon, Min Jeong Jo, Myeong Kyun Yoo, So Yeon Park, Sunghyun Bong, Jonghyuk Kim, Seonmin Park, Yeseung Lee, Yuseon Shin, Hye Jin Lee, Jin-Seok Kim, Chun-Woong Park, and Dae Hwan Shin*, International Journal of Nanomedicine, 21, 1–39 (2026)
4. Evaluation of Anticancer Efficacy of D-α-Tocopheryl Polyethylene-Glycol Succinate and Soluplus® Mixed Micelles Loaded with Olaparib and Rapamycin Against Ovarian Cancer, Yu Been Shin*, Ju-Yeon Choi*, Moon Sup Yoon, Myeong Kyun Yoo, Dae Hwan Shin*, and Jeong-Won Lee*, International Journal of Nanomedicine, 19, 7871–7893 (2024)
5. Gemcitabine and Rapamycin-Loaded Mixed Polymeric Thermogel for Metastatic Pancreatic Cancer Therapy, Seo Yeon Kim¹, Min Jeong Jo¹, Moon Sup Yoon¹, Chae Eun Jin, Yu Been Shin, Jae Min Lee, Hee Ji Shin, Joon Gyo Oh, Jae Min Cho, Hyunjun Kim, Hyunjin Park, Yong-Won Choi, Chun-Woong Park, Jin-Seok Kim, and Dae Hwan Shin*, Journal of Controlled Release, 360, 796–809 (2023)

Selected Patents

1. Method for preparing tumoroids based on a luminescent gastric cancer cell line enabling continuous cytotoxicity analysis for evaluating anticancer efficacy, Korean Patent No. 10-2910491 (2026)
2. TPGS-Soluplus micelles encapsulating olaparib and rapamycin and uses thereof, Korean Patent No. 10-2913992 (2026)
3. Microfluidic device for confirming sustained anticancer activity of drugs and the EPR effect of drug-loaded nanoparticles, Korean Patent No. 10-2942137 (2026)
4. Thermosensitive PLGA-PEG-PLGA hydrogel encapsulating gemcitabine and rapamycin and uses thereof, Korean Patent No. 10-2885955 (2025)
5. Polyethylene glycol-polycaprolactone copolymer micelles containing fenbendazole and rapamycin, and uses thereof, Korean Patent No. 10-2021-0091711 (2023)

Lab of Pharmaceutics